Thermalin’s Insulin Analog T-1123 and StampPump™ Presented at The 13th International Conference on Advanced Technologies & Treatments for Diabetes
Madrid, Spain, February 20, 2020 – Thermalin Inc., a privately held biotechnology company with its main laboratories in Cleveland, Ohio, USA, today shared initial details of the novel insulin analog, T‑1123 along with StampPump, the groundbreaking delivery device that the analog enables, with the diabetes scientific community at The 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). Thermalin was awarded a grant from ATTD to participate in The International Fair of New Technologies in Diabetes, where start-ups and emerging companies exhibited cutting-edge technologies and medical devices for diabetes treatment. In addition to one-on-one discussions with conference participants at the Thermalin booth in the exhibit hall, Thermalin’s Chief Scientific Officer Dod Michael, Ph.D. presented lectures to two different audiences.
Dr. Michael discussed T-1123, Thermalin’s first-in-class, stabilized insulin analog that has an ultra-rapid time-action profile in both U-100 and U-500 formulations. He shared that both the U-100 and U-500 formulations of T-1123 show remarkably enhanced resistance to thermally-induced physical loss of potency and that T-1123 demonstrates six-fold less potency to stimulate proliferation of human breast cancer cells compared to human insulin. This unprecedented confluence of favorable features promises to enable the factory-filling of today’s insulin pump reservoirs with a U‑100 formulation of T-1123 as well as use of the U-500 formulation of T-1123 in Thermalin’s StampPump—a truly disruptive innovation in the medical care of those with diabetes.
Dr. Michael also discussed StampPump, a postage stamp-sized glucose management system that will deliver the concentrated, ultra-rapid-acting formulation of T-1123 for people with Type 1 (T1D) or Type 2 diabetes mellitus (T2D). StampPump is a wearable, skin-adhering, miniaturized (36 x 33 x 6.5 mm, 8 g) closed-loop insulin delivery system that is easily placed using a disposable applicator, delivers insulin for a full week, and is discarded after use. The device will have multiple sensors onboard to improve closed-loop glucose control and also will be connected via Bluetooth to both an external continuous glucose monitor (CGM) and a mobile device and through that device to the cloud. StampPump will carry up to 600 units of the T‑1123 insulin analog in a 1.2 ml reservoir that is filled at the time of manufacture. Due to the stability of T‑1123, the factory-filled StampPump will be stored at room temperature on the pharmacy shelf and in the patient’s home instead of in a refrigerator.
Thermalin intends to start IND-enabling work for T-1123 in 2020 and to test a functional, right-sized prototype of StampPump in 2021.
Thermalin is developing next-generation insulin solutions for people with T1D and T2D. Thermalin’s programs include (1) clinical candidate T-1123—a stabilized insulin analog that is ultra-rapid at both U-100 and U-500, (2) StampPump—a miniaturized glucose management system that will deliver the concentrated, ultra-rapid-acting formulation of T-1123, (3) basal and mix insulins that never need refrigeration, and (4) a glucose-responsive insulin that protects against hypoglycemia by losing potency when glucose levels are below normal. For more information, please visit www.thermalin.com. For background on insulin therapy for diabetes, please visit www.thermalin.com/background.
E-mail: [email protected]